{"entity":{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","aka":[],"tldr":"Poseida developed off-the-shelf CAR T-cell therapies made from healthy donor cells rather than from each patient, for multiple myeloma and B-cell cancers. Roche bought the company in early 2025 for up to about $1.5 billion.","summary":"Poseida Therapeutics was a clinical-stage company pioneering donor-derived (allogeneic) CAR T-cell therapies, with non-viral piggyBac gene engineering and manufacturing capabilities. Lead programme P-BCMA-ALLO1 is an allogeneic BCMA-directed CAR T for relapsed or refractory multiple myeloma with RMAT and Orphan Drug designations. P-CD19CD20-ALLO1 is a phase 1 allogeneic dual CAR T in B-cell malignancies, also being investigated in multiple sclerosis and lupus, and P-MUC1C-ALLO1 is a phase 1 allogeneic CAR T in solid tumours. Several programmes were already partnered with Roche under a 2022 collaboration. Roche agreed in November 2024 to acquire Poseida for $9.00 per share in cash plus a contingent value right worth up to $4.00 per share, a total of up to about $1.5 billion, and the merger closed on 8 January 2025. Legacy programmes continue within Genentech and the former Nasdaq ticker PSTX was retired.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.gene.com/poseida"},{"label":"Roche to acquire Poseida (November 2024)","url":"https://www.roche.com/media/releases/med-cor-2024-11-26b"},{"label":"Completion of merger (8-K, January 2025)","url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/d874651d8k.htm"}],"tags":[],"related":[],"cancers":["multiple-myeloma","dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["bcma","cd19","cd20"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker PSTX. The CVR portion of the deal value is contingent on milestones."],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","website":"https://www.gene.com/poseida","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":1500000000,"source":"https://www.roche.com/media/releases/med-cor-2024-11-26b","note":"$9.00 per share in cash (about $1.0 billion equity value) plus a contingent value right of up to $4.00 per share, total deal value up to about $1.5 billion; announced 26 November 2024, completed 8 January 2025"}],"acquiredBy":"roche-genentech"},"route":"/companies/poseida-therapeutics/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}